Skip to main content
. 2022 Feb 8;23(3):1911. doi: 10.3390/ijms23031911

Figure 3.

Figure 3

AKR1B10 is a key regulator of the cytokines production in RAW264.7 and H1299 cells, whose activity may be counteracted by pharmacological inhibitors. (A) Expression of the cytokines IL-6, TNFα and IL-1β, measured by RT-PCR in RAW264.7 macrophage cells after 12 h of 0 µg (Lipofectamine), 1 µg, 2 µg or 3 µg of peGFP-AKR1B10GFP plasmid transfection; (B) expression of the cytokines IL-6, TNFα and IL-1β, measured by RT-PCR in lung cancer cells H1299 after 12 h of 0 (Lipofectamine) or 1 µg of peGFP-AKR1B10GFP plasmid transfection; (C) effect of an AKR1B10 inhibitor (Zopolrestat at the indicated concentrations in mM) on cytokines expression in RAW264.7 cells stressed for 6 h by LPS, at the concentration of 0.5 µg·mL−1; LPS: Lipopolysaccharides; Zopol: Zopolrestat; (n = 3–5; mean ± SEM). #: difference compared to Control and pEGFP-AKR1B10GFP [0 µg] ( ###: p < 0.001); *: difference compared to pEGFP-AKR1B10GFP [3 µg] (*: p < 0.05); †: difference compared to LPS [0.5 µg·mL−1] and Zopolrestat [40 mM] (†: p < 0.05); §: difference compared to Control (§: p < 0.05; §§: p < 0.01); µ: difference compared to pEGFP-AKR1B10GFP [0 µg] (µ: p < 0.05); ‡: difference compared to LPS [0.5 µg·mL−1] and Zopolrestat [0 mM] (‡: p < 0.05; ‡‡: p < 0.01; ‡‡‡: p < 0.001).